Patient-reported symptoms and interest in symptom monitoring in HCC treated with locoregional therapies: A qualitative study.

Autor:	Moon AM; Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina, USA.; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA., Cook S; Virginia Commonwealth School of Medicine, Richmond, Virginia, USA., Swier RM; University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA., Sanoff HK; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.; Division of Oncology, University of North Carolina, Chapel Hill, North Carolina, USA., Kappelman MD; Department of Pediatrics, Division of Pediatric Gastroenterology, University of North Carolina, Chapel Hill, North Carolina, USA., Wagner LI; Department of Health Policy and Management, University of North Carolina, Chapel Hill, North Carolina, USA., Barritt AS 4th; Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina, USA., Singal AG; Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, Texas, USA., Shah ND; Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina, USA., Mauro DM; Division of Vascular Interventional Radiology, University of North Carolina, Chapel Hill, North Carolina, USA., Yanagihara TK; Department of Radiation Oncology, University of North Carolina, Chapel Hill, North Carolina, USA., Gerber DA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.; Department of Surgery, University of North Carolina, Chapel Hill, North Carolina, USA., Fried MW; Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina, USA., Brown C; Department of Medicine, University of Texas at Austin, Austin, Texas, USA., Waheed M; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.; Connected Health Applications and Interventions (CHAI) Core, University of North Carolina, Chapel Hill, North Carolina, USA., Teal R; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.; Connected Health Applications and Interventions (CHAI) Core, University of North Carolina, Chapel Hill, North Carolina, USA., Evon DM; Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina, USA.
Jazyk:	angličtina
Zdroj:	Hepatology communications [Hepatol Commun] 2023 Nov 06; Vol. 7 (11). Date of Electronic Publication: 2023 Nov 06 (Print Publication: 2023).
DOI:	10.1097/HC9.0000000000000315
Abstrakt:	Background: Patient-reported outcomes (PRO) measures relevant to domains most important to patients with HCC who received locoregional therapies are needed to advance patient-centered research. Furthermore, electronic PRO monitoring in clinical care has been shown to reduce hospitalizations and deaths in patients with other cancers. We conducted a qualitative study among patients with HCC who recently received locoregional therapies to (1) identify common and distressing posttreatment symptoms to prioritize PRO domain selection and (2) gauge interest in an electronic PRO symptom monitoring system. Methods: We performed semi-structured telephone interviews among adult patients who received locoregional therapies (median of 26 days after treatment) for treatment-naïve HCC at a single tertiary care center. Interviews were conducted until thematic saturation was reached. Qualitative content analysis was conducted to identify emerging themes and sub-themes. Results: Ten of 26 patients (38%) reported at least 1 symptom before treatment. In contrast, all participants (n = 26) with recently treated HCC reported at least 1 posttreatment physical symptom, with the most common being appetite loss (73%), fatigue (58%), abdominal pain (46%), and nausea (35%). Most participants (77%) stated they saw potential benefits in posttreatment ePRO symptom monitoring. Conclusions: Posttreatment symptoms after HCC locoregional therapies are common and often severe. These data can inform and prioritize PRO domain selection. Patients are interested in ePRO monitoring to monitor and proactively address posttreatment symptoms. Given the clinical benefits in patients with metastatic cancers, ePRO monitoring warrants investigation in patients with HCC. (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu